Dopamine D-3 receptor as a new pharmacological target for the
treatment of depression

J 2013

Dopamine D-3 receptor as a new pharmacological target for the treatment of depression

LEGGIO, Gian Marco, Salvatore SALOMONE, Claudio BUCOLO, Chiara PLATANIA, Vincenzo MICALE et. al.

Základní údaje

Originální název

Dopamine D-3 receptor as a new pharmacological target for the treatment of depression

Autoři

LEGGIO, Gian Marco (380 Itálie), Salvatore SALOMONE (380 Itálie), Claudio BUCOLO (380 Itálie), Chiara PLATANIA (380 Itálie), Vincenzo MICALE (380 Itálie, garant, domácí), Filippo CARACI (380 Itálie) a Filippo DRAG (380 Itálie)

Vydání

European Journal of Pharmacology, AMSTERDAM, Elsevier, 2013, 0014-2999

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.684

Kód RIV

RIV/00216224:14740/13:00072054

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1016/j.ejphar.2013.07.022

UT WoS

000327487200005

Klíčová slova anglicky

Depression; Dopamine D-3 receptor; Brain-derived neurotrophic factor; Partial agonist; Treatment-resistant depression; Aripiprazole

Štítky

ok, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 2. 2014 19:26, Olga Křížová

Anotace

V originále

A substantial proportion of depressed patients do not respond to current antidepressant drug therapies. So far, antidepressant drugs have been developed based on the "monoaminergic hypothesis" of depression, which considers a synaptic deficiency in 5-hydroxytryptamine (5-HT; serotonin) or noradrenaline as main cause. More recently, the dopaminergic system has been implicated in the efficacy of some antidepressants, such as desipramine, amineptine, nomifensine. Dysfunction of dopaminergic neurotransmission within the mesolimbic system may contribute to anhedonia, loss of motivation and psychomotor retardation in severe depressive disorders. Dopamine D-3 receptor subtype is located both pre- and postsynaptically in brain areas regulating motivation and reward-related behavior and has been implicated in depression-like behaviors. Activity of mesolimbic dopamine neurons in the reward circuit is a key determinant of behavioral susceptibility/resilience to chronic stress, which plays a central role in the pathogenesis of depression. Dopamine D-3 receptor expression and function are both down-regulated in stress and depression, and these changes are reversed by antidepressant treatments, suggesting that enhanced dopaminergic neurotransmission mediated by dopamine D-3 receptor participates in adaptive changes related to antidepressant activity. Of note, brain derived neurotrophic factor (BDNF) controls the expression of the dopamine 03 receptor in some brain areas and BEM induction by antidepressant treatments is related to their behavioral activity. A number of experimental drugs in pre-clinical or clinical development, including aripiprazole and cariprazine, may act as antidepressants because of their partial agonist activity at dopamine D-3 receptors. These preclinical and clinical data are discussed in the present review.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

Citovat

LEGGIO, Gian Marco, Salvatore SALOMONE, Claudio BUCOLO, Chiara PLATANIA, Vincenzo MICALE, Filippo CARACI a Filippo DRAG. Dopamine D-3 receptor as a new pharmacological target for the treatment of depression. European Journal of Pharmacology. AMSTERDAM: Elsevier, 2013, roč. 719, 1-3, s. 25-33. ISSN 0014-2999. Dostupné z: https://dx.doi.org/10.1016/j.ejphar.2013.07.022.

@article{1165242,
   author = {Leggio, Gian Marco and Salomone, Salvatore and Bucolo, Claudio and Platania, Chiara and Micale, Vincenzo and Caraci, Filippo and Drag, Filippo},
   article_location = {AMSTERDAM},
   article_number = {1-3},
   doi = {http://dx.doi.org/10.1016/j.ejphar.2013.07.022},
   keywords = {Depression; Dopamine D-3 receptor; Brain-derived neurotrophic factor; Partial agonist; Treatment-resistant depression; Aripiprazole},
   language = {eng},
   issn = {0014-2999},
   journal = {European Journal of Pharmacology},
   title = {Dopamine D-3 receptor as a new pharmacological target for the treatment of depression},
   volume = {719},
   year = {2013}
}

TY  - JOUR
ID  - 1165242
AU  - Leggio, Gian Marco - Salomone, Salvatore - Bucolo, Claudio - Platania, Chiara - Micale, Vincenzo - Caraci, Filippo - Drag, Filippo
PY  - 2013
TI  - Dopamine D-3 receptor as a new pharmacological target for the treatment of depression
JF  - European Journal of Pharmacology
VL  - 719
IS  - 1-3
SP  - 25-33
EP  - 25-33
PB  - Elsevier
SN  - 00142999
KW  - Depression
KW  - Dopamine D-3 receptor
KW  - Brain-derived neurotrophic factor
KW  - Partial agonist
KW  - Treatment-resistant depression
KW  - Aripiprazole
N2  - A substantial proportion of depressed patients do not respond to current antidepressant drug therapies. So far, antidepressant drugs have been developed based on the "monoaminergic hypothesis" of depression, which considers a synaptic deficiency in 5-hydroxytryptamine (5-HT; serotonin) or noradrenaline as main cause. More recently, the dopaminergic system has been implicated in the efficacy of some antidepressants, such as desipramine, amineptine, nomifensine. Dysfunction of dopaminergic neurotransmission within the mesolimbic system may contribute to anhedonia, loss of motivation and psychomotor retardation in severe depressive disorders. Dopamine D-3 receptor subtype is located both pre- and postsynaptically in brain areas regulating motivation and reward-related behavior and has been implicated in depression-like behaviors. Activity of mesolimbic dopamine neurons in the reward circuit is a key determinant of behavioral susceptibility/resilience to chronic stress, which plays a central role in the pathogenesis of depression. Dopamine D-3 receptor expression and function are both down-regulated in stress and depression, and these changes are reversed by antidepressant treatments, suggesting that enhanced dopaminergic neurotransmission mediated by dopamine D-3 receptor participates in adaptive changes related to antidepressant activity. Of note, brain derived neurotrophic factor (BDNF) controls the expression of the dopamine 03 receptor in some brain areas and BEM induction by antidepressant treatments is related to their behavioral activity. A number of experimental drugs in pre-clinical or clinical development, including aripiprazole and cariprazine, may act as antidepressants because of their partial agonist activity at dopamine D-3 receptors. These preclinical and clinical data are discussed in the present review.
ER  -

LEGGIO, Gian Marco, Salvatore SALOMONE, Claudio BUCOLO, Chiara PLATANIA, Vincenzo MICALE, Filippo CARACI a Filippo DRAG. Dopamine D-3 receptor as a new pharmacological target for the treatment of depression. \textit{European Journal of Pharmacology}. AMSTERDAM: Elsevier, 2013, roč.~719, 1-3, s.~25-33. ISSN~0014-2999. Dostupné z: https://dx.doi.org/10.1016/j.ejphar.2013.07.022.

Podrobný výpis o publikaci